Literature DB >> 12003054

A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot.

Jeff A Sloan1, Daniel J Sargent, Jed Lindman, Cristine Allmer, Delfino Vargas-Chanes, Edward T Creagan, James A Bonner, Michael J O'Connell, Robert J Dalton, Kendrith M Rowland, Burke J Brooks, John A Laurie.   

Abstract

One of the challenges of interpreting a Quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) analysis is examining the sensitivity of conclusions that may be drawn to varying values of the utility coefficients for days with toxicity and days after disease progression. We present a graphic that parsimoniously displays the impact on median Q-TWiST survival across treatment groups of varying values of the utility coefficients. The goal of the graphic is to present a concise Q-TWiST analysis. We use Zhao and Tsiatis (Biometrika 1997; 84(2): 339-348) to adjust for the bias in Kaplan-Meier (K-M) estimates. The graphic contains bounds that approximate points for which statistical significance would be achieved by comparing the median Q-TWiST survival between treatment alternatives for each value of the utility coefficients. The plot may be generalized to compare Q-TWiST means, medians or percentiles across treatment groups. We demonstrate the application of the Q-TWiST plot through a re-analysis of a randomized phase III North Central Cancer Treatment Group (NCCTG) clinical trial of recombinant Interferon-2alpha in patients with malignant melanoma. We explore alternative options to customize the graphic representation for other data sets drawn from several NCCTG clinical trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003054     DOI: 10.1023/a:1014401516011

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  11 in total

1.  Decision analysis in locally advanced non-small-cell lung cancer: is it useful?

Authors:  M D Brundage; P A Groome; D Feldman-Stewart; J R Davidson; W J Mackillop
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

2.  Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821.

Authors:  S K Parsons; S Gelber; B F Cole; Y Ravindranath; A Ogden; A M Yeager; M Chang; J Shuster; H J Weinstein; R D Gelber
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

3.  The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients.

Authors:  M E Cowen; B J Miles; D F Cahill; R B Giesler; J R Beck; M W Kattan
Journal:  Med Decis Making       Date:  1998 Oct-Dec       Impact factor: 2.583

4.  Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff.

Authors:  S J Jansen; A M Stiggelbout; P P Wakker; T P Vliet Vlieland; J W Leer; M A Nooy; J Kievit
Journal:  Med Decis Making       Date:  1998 Oct-Dec       Impact factor: 2.583

5.  Whose utilities for decision analysis?

Authors:  N F Boyd; H J Sutherland; K Z Heasman; D L Tritchler; B J Cummings
Journal:  Med Decis Making       Date:  1990 Jan-Mar       Impact factor: 2.583

6.  A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1).

Authors:  Jeff A Sloan; James A Bonner; Shauna L Hillman; Cristine Allmer; Thomas G Shanahan; Burke J Brooks; Randolph S Marks; Delfino Vargas-Chanes; James R Jett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

7.  Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.

Authors:  E T Creagan; R J Dalton; D L Ahmann; S H Jung; R F Morton; R M Langdon; J Kugler; L J Rodrigue
Journal:  J Clin Oncol       Date:  1995-11       Impact factor: 44.544

8.  Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores.

Authors:  A M Stiggelbout; G M Kiebert; J Kievit; J W Leer; G Stoter; J C de Haes
Journal:  Med Decis Making       Date:  1994 Jan-Mar       Impact factor: 2.583

9.  Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: a comparison of state and process utilities.

Authors:  J van der Donk; P C Levendag; A J Kuijpers; F H Roest; J D Habbema; C A Meeuwis; P I Schmitz
Journal:  J Clin Oncol       Date:  1995-09       Impact factor: 44.544

10.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.

Authors:  A Goldhirsch; R D Gelber; R J Simes; P Glasziou; A S Coates
Journal:  J Clin Oncol       Date:  1989-01       Impact factor: 44.544

View more
  6 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2003

2.  Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

Authors:  David F McDermott; Ruchit Shah; Komal Gupte-Singh; Javier Sabater; Linlin Luo; Marc Botteman; Sumati Rao; Meredith M Regan; Michael Atkins
Journal:  Qual Life Res       Date:  2018-09-06       Impact factor: 4.147

3.  Role of exclusive chemotherapy as first line treatment in oligodendroglioma.

Authors:  Marie Pierre Sunyach; Anne Jouvet; David Perol; Emmanuel Jouanneau; Jacques Guyotat; Laurence Gignoux; Christian Carrie; Didier Frappaz
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

4.  Calibration of quality-adjusted life years for oncology clinical trials.

Authors:  Jeff A Sloan; Daniel J Sargent; Paul J Novotny; Paul A Decker; Randolph S Marks; Heidi Nelson
Journal:  J Pain Symptom Manage       Date:  2013-11-15       Impact factor: 3.612

5.  Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance).

Authors:  Brittny T Major-Elechi; Paul J Novotny; Jasvinder A Singh; James A Bonner; Amylou C Dueck; Daniel J Sargent; Axel Grothey; Jeff A Sloan
Journal:  Int J Stat Med Res       Date:  2018-11-16

6.  Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.

Authors:  B Sherrill; J Wang; S Kotapati; K Chin
Journal:  Br J Cancer       Date:  2013-06-20       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.